<abstract xmlns="http://www.w3.org/1999/xhtml">

Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a prothrombotic effect after being activated by thrombin, but also through its antifibrinolytic action, stabilizing the formed clot.
Hereditary deficiency of FXI causes haemophilia C - a disease manifested by an usually provoked, small to moderate mucosal bleeding. People with severe FXI deficiency have a low risk of thrombotic events. Conversely, increased FXI values have been found to be associated with increased risk of venous thromboembolism and ischemic stroke.
Lowering serum FXI levels has become a treatment target for the prevention of thrombotic events. New pharmacological agents - FXI inhibitors - have been investigated in phase II clinical trials, with promising results in terms of efficacy and safety in the prevention of thrombotic events. FXI inhibitors are emerging as new anticoagulant agents with broad indication prospects beyond direct oral anticoagulants and vitamin K antagonists.
</abstract>

Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a prothrombotic effect after being activated by thrombin, but also through its antifibrinolytic action, stabilizing the formed clot.
Hereditary deficiency of FXI causes haemophilia C - a disease manifested by an usually provoked, small to moderate mucosal bleeding. People with severe FXI deficiency have a low risk of thrombotic events. Conversely, increased FXI values have been found to be associated with increased risk of venous thromboembolism and ischemic stroke.
Lowering serum FXI levels has become a treatment target for the prevention of thrombotic events. New pharmacological agents - FXI inhibitors - have been investigated in phase II clinical trials, with promising results in terms of efficacy and safety in the prevention of thrombotic events. FXI inhibitors are emerging as new anticoagulant agents with broad indication prospects beyond direct oral anticoagulants and vitamin K antagonists.

Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives

“Carol Davila” University of Medicine and Pharmacy

Department of Hematology, Emergency University Hospital of Bucharest

Department of Functional Sciences, Division of Physiology

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives"}

Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a...

Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives

Publié en ligne: 28 déc. 2023

Pages: 91 - 100

Reçu: 18 sept. 2023

DOI: https://doi.org/10.2478/rjim-2023-0034

Mots clés
factor XI deficiency, factor XI Inhibitors, hemostasis, thrombosis, new class of anticoagulants, Hemophilia C

© 2023 Ana-Maria Vlădăreanu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives

Publié en ligne: 28 déc. 2023

Pages: 91 - 100

Reçu: 18 sept. 2023

DOI: https://doi.org/10.2478/rjim-2023-0034

Mots clésfactor XI deficiency, factor XI Inhibitors, hemostasis, thrombosis, new class of anticoagulants, Hemophilia C

© 2023 Ana-Maria Vlădăreanu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
factor XI deficiency, factor XI Inhibitors, hemostasis, thrombosis, new class of anticoagulants, Hemophilia C